<DOC>
	<DOCNO>NCT00033384</DOCNO>
	<brief_summary>RATIONALE : CI-1040 may stop growth tumor block enzymes necessary cancer cell growth stop blood flow tumor . PURPOSE : Phase II trial study effectiveness CI-1040 treating patient metastatic unresectable breast , colon , pancreatic , non-small cell lung cancer .</brief_summary>
	<brief_title>CI-1040 Treating Patients With Advanced Breast , Colon , Pancreatic , Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity CI-1040 patient non-small cell lung , breast , colon , pancreatic cancer . - Determine safety profile drug patient . - Assess quality life ( overall tumor type ) patient treat drug . - Determine relationship study drug concentration antitumor response patient target suppression safety drug . - Correlate target suppression ( pERK ) antitumor effect drug patient . - Correlate mRNA expression profile tumor antitumor effect drug patient . OUTLINE : This multicenter study . Patients stratify accord tumor type ( non-small cell lung v breast v colon v pancreas ) . Patients receive oral CI-1040 twice daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess baseline every 28 day first 6 month study therapy . Patients follow every 2 month . PROJECTED ACCRUAL : A total 52-172 patient ( 13-43 per stratum ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic inoperable nonsmall cell lung , breast , colon cancer duct cell carcinoma exocrine pancreas Bidimensionally measurable lesion previously irradiate New lesion develop previously irradiate field may use measurable disease No brain metastases Patients prior brain metastasis allow provide undergone prior resection metastasis and/or 1 prior course cranial irradiation , new site brain metastasis since , worsen CNS symptom , discontinue prior corticosteroid least 30 day Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 2 time ULN ( 5 time ULN due liver involvement ) Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day study participation Capable swallow intact study medication capsule Capable follow instruction regard study medication daily caregiver administer study medication No concurrent serious infection No lifethreatening illness unrelated tumor No prior concurrent malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior immunotherapy biologic therapy Chemotherapy : At least 4 week since prior cytotoxic chemotherapy No 1 prior cytotoxic chemotherapy regimen metastatic nonsmall cell lung colon cancer No 2 prior cytotoxic chemotherapy regimen breast cancer No prior cytotoxic chemotherapy pancreatic cancer Endocrine therapy : See Disease Characteristics At least 2 week since prior hormonal therapy Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>